Stryker Co. (NYSE:SYK) Shares Bought by Oakworth Capital Inc.

Oakworth Capital Inc. grew its holdings in Stryker Co. (NYSE:SYK) by 1.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,908 shares of the medical technology company’s stock after acquiring an additional 100 shares during the period. Oakworth Capital Inc.’s holdings in Stryker were worth $1,769,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in SYK. Bremer Bank National Association boosted its holdings in shares of Stryker by 4.0% in the 4th quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock valued at $266,000 after buying an additional 34 shares during the period. Simon Quick Advisors LLC lifted its stake in shares of Stryker by 3.0% in the 4th quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock worth $347,000 after acquiring an additional 34 shares during the period. Consolidated Portfolio Review Corp lifted its stake in shares of Stryker by 3.6% in the 4th quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock worth $294,000 after acquiring an additional 34 shares during the period. MBL Wealth LLC lifted its stake in shares of Stryker by 4.6% in the 4th quarter. MBL Wealth LLC now owns 850 shares of the medical technology company’s stock worth $255,000 after acquiring an additional 37 shares during the period. Finally, PDS Planning Inc lifted its stake in shares of Stryker by 3.0% in the 3rd quarter. PDS Planning Inc now owns 1,318 shares of the medical technology company’s stock worth $360,000 after acquiring an additional 38 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

SYK stock traded down $1.07 during mid-day trading on Wednesday, reaching $336.59. 663,881 shares of the company traded hands, compared to its average volume of 1,246,687. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. The company has a market capitalization of $128.06 billion, a P/E ratio of 40.93, a P/E/G ratio of 2.73 and a beta of 0.89. The company has a fifty day moving average price of $350.70 and a 200-day moving average price of $311.86.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The company had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the previous year, the firm earned $3.00 earnings per share. Stryker’s revenue was up 11.8% on a year-over-year basis. As a group, analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 0.95%. The ex-dividend date is Wednesday, March 27th. Stryker’s payout ratio is 38.79%.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of research reports. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Royal Bank of Canada boosted their target price on shares of Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a report on Monday. Evercore ISI boosted their price target on shares of Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Truist Financial boosted their price target on shares of Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a report on Wednesday, January 31st. Finally, Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 price objective on the stock in a research report on Wednesday, January 31st. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $339.22.

Insider Buying and Selling

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the sale, the director now owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The disclosure for this sale can be found here. Insiders sold 212,109 shares of company stock worth $72,845,768 in the last quarter. 5.50% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.